Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway

Endocrine Journal

Volumn 58, Issue 9, 2011, Pages 761-768

  Xie, Xi ^a   Li, Wenyuan ^b   Lan, Tian ^a   Liu, Weihua ^a   Peng, Jing ^a   Huang, Kaipeng ^a   Huang, Juan ^a   Shen, Xiaoyan ^a   Liu, Peiqing ^a   Huang, Heqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Akt signaling pathway; Berberine; Diabetic mouse; Glucokinase; GSK 3

Indexed keywords

BERBERINE; GLUCOKINASE; GLUCOSE; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN RECEPTOR KINASE; PROTEIN KINASE B;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; HYPERGLYCEMIA; HYPOGLYCEMIA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; BERBERINE; BLOOD GLUCOSE; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; GLUCOKINASE; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; HYPERGLYCEMIA; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 80053923650     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K11E-024     Document Type: Article

References (35)

1. S. Wild, G. Roglic, A. Green, R. Sicree and H. King (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
2. L. Rossetti and M. R. Lauglin (1989) Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 84: 892-899.
3. R. V. Dimlich, S. F. Townsend and F. D. Reilly (1982) Mast cell degranulation, hepatic glycogen depletion, and hyperglycemia in Compound 48/80 or pilocarpinetreated rats. Hepatology 2: 372-378.
4. J. Zdychova and R. Komers (2005) Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiol Res 54: 1-16.
5. S. Kagawa, Y. Soeda, H. Ishihara, T. Oya, M. Sasahara, S. Yaguchi, R. Oshita, T. Wada, H. Tsuneki and T. Sasaoka (2008) Impact of transgenic overexpression of SH2-containing inositol 5'-phosphatase 2 on glucose metabolism and insulin signaling in mice. Endocrinology 149: 642-650.
6. A. King and E. Gottlieb (2009) Glucose metabolism and programmed cell death: an evolutionary and mechanistic perspective. Curr Opin Cell Biol 21: 885-893.
7. P. B. Iynedjian, R. A. Roth, M. Fleischmann and A. Gjinovci (2000) Activation of protein kinase B/cAkt in hepatocytes is sufficient for the induction of expression of the gene encoding glucokinase. Biochem J 351: 621-627.
8. P. G. Ribaux and P. B. Iynedjian (2003) Analysis of the role of protein kinase B (cAKT) in insulin-dependent induction of glucokinase and sterol regulatory elementbinding protein 1 (SREBP1) mRNAs in hepatocytes. Biochem J 376: 697-705.
9. A. Krook, Y. Kawano, X. M. Song, S. Efendic, R. A. Roth, H. Wallberg-Henriksson and J. R. Zierath (1997) Improved glucose tolerance restores insulin-stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto-Kakizaki rats. Diabetes 46: 2110-2114.
10. A. Krook, R. A. Roth, X. J. Jiang, J. R. Zierath and H. Wallberg-Henriksson (1998) Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes 47: 1281-1286.
11. S. Varma, B. K. Lal, R. F. Zheng, J. W. Breslin, S. Saito, P. J. Pappas, R. W. Hobson and W. N. Duran (2005) Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol-Heart C 289: H1744-H1751.
12. K. Maiese, Z. Z. Chong and Y. C. Shang (2007) Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 14: 1729-1738.
13. J. Singh and P. Kakkar (2009) Antihyperglycemic and antioxidant effect of Berberis aristata root extract and its role in regulating carbohydrate metabolism in diabetic rats. J Ethnopharmacol 123: 22-26.
14. W. J. Kong, J. Wei, P. Abidi, M. H. Lin, S. Inaba, C. Li, Y. L. Wang, Z. Z. Wang, S. Y. Si, H. N. Pan, S. K. Wang, J. D. Wu, Y. Wang, Z. R. Li, J. W. Liu and J. D. Jiang (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344-1351.
15. L. Q. Tang, W. Wei, L. M. Chen and S. Liu (2006) Effects of berberine on diabetes induced by alloxan and a highfat/ high-cholesterol diet in rats. J Ethnopharmacol 108: 109-115.
16. J. Yin, H. Xing and H. Ye (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57: 712-717.
17. Y. F. Zhang, X. Y. Li, D. J. Zou, W. Liu, J. L. Yang, N. Zhu, L. Huo, M. A. Wang, J. Hong, P. H. Wu, G. G. Ren and G. Ning (2008) Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocr Metab 93: 2559-2565.
18. H. A. Jung, N. Y. Yoon, H. J. Bae, B. S. Min and J. S. Choi (2008) Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase. Arch Pharm Res 31: 1405-1412.
19. W. H. Liu, P. Q. Liu, S. Tao, Y. H. Deng, X. J. Li, T. Lan, X. Y. Zhang, F. F. Guo, W. G. Huang, F. Y. Chen, H. Q. Huang and S. F. Zhou (2008) Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Arch Biochem Biophys 475: 128-134.
20. J. P. Wang, H. Q. Huang, P. Q. Liu, F. T. Tang, J. Qin, W. G. Huang, F. Y. Chen, F. F. Guo, W. H. Liu and B. Yang (2006) Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. Eur J Pharmacol 553: 297-303.
21. A. V. Chibalin, Y. Leng, E. Vieira, A. Krook, M. Bjoernholm, Y. C. Long, O. Kotova, Z. H. Zhong, F. Sakane, T. Steiler, C. Nylen, J. J. Wang, M. Laakso, M. K. Topham, M. Gilbert, H. Wallberg-Henriksson and J. R. Zierath (2008) Downregulation of diacylglycerol kinase delta contributes to hyperglycemia-induced insulin resistance. Cell 132: 375-386.
22. G. Patane, M. Anello, S. Piro, R. Vigneri, F. Purrello and A. M. Rabuazzo (2002) Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-gamma inhibition. Diabetes 51: 2749-2756.
23. E. Carvalho, C. Rondinone and U. Smith (2000) Insulin resistance in fat cells from obese Zucker rats-evidence for an impaired activation and translocation of protein kinase B and glucose transporter 4. Mol Cell Biochem 206: 7-16.
24. E. L. Whiteman, H. Cho and M. J. Birnbaum (2002) Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 13: 444-451.
25. X. Li, B. Monks, Q. Ge and M. J. Birnbaum (2007) Akt/ PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 447: 1012-1016.
26. J. L. Buescher and C. J. Phiel (2010) A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity. J Biol Chem 285: 7957-7963.
27. P. Cohen and S. Frame (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769-776.
28. T. Force and J. R. Woodgett (2009) Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 284: 9643-9647.
29. L. Agius (2009) Targeting Hepatic Glucokinase in Type 2 Diabetes Weighing the Benefits and Risks. Diabetes 58: 18-20.
30. J. L. McKinney, H. N. Cao, J. F. Robinson, D. L. Metzger, D. C. Riddell, S. R. Sanderson, D. Pacaud, J. Ho and R. A. Hegele (2004) Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY). Clin Invest Med 27: 135-141.
31. K. K. Osbak, K. Colclough, C. Saint-Martin, N. L. Beer, C. Bellanne-Chantelot, S. Ellard and A. L. Gloyn (2009) Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30: 1512-1526.
32. R. C. Page, A. T. Hattersley, J. C. Levy, B. Barrow, P. Patel, D. Lo, J. S. Wainscoat, M. A. Permutt, G. I. Bell and R. C. Turner (1995) Clinical characteristics of subjects with a missense mutation in glucokinase. Diabet Med 12: 209-217.
33. B. Glaser, P. Kesavan, M. Heyman, E. Davis, A. Cuesta, A. Buchs, C. A. Stanley, P. S. Thornton, M. A. Permutt, F. M. Matschinsky and K. C. Herold (1998) Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338: 226-230.
34. G. Yili, P. Hong and S. Xiqun (2009) Effects of Alloxan-Induced Diabetes on the Expression of Insulin Signal Transmission Molecules. Wuhan Univ J Nat Sci 14: 447-451.
35. C.H. Chen, Y.B. Zhang, C. Huang (2010) Berberine inhibits PTP1B activity and mimics insulin action. Biochem Bioph Res Co 397: 543-547.